Monge, SusanaHumphreys, JamesNicolay, NathalieBraeye, ToonVan Evercooren, IzaakHolm Hansen, ChristianEmborg, Hanne‐DortheSacco, ChiaraMateo‐Urdiales, AlbertoCastilla, JesúsMartínez‐Baz, Ivánde Gier, BrechjeHahné, SusanMeijerink, HintaKristoffersen, Anja BråthenMachado, AusendaSoares, PatriciaNardone, AnthonyBacci, SabrinaKissling, EstherNunes, Baltazar2025-03-052025-03-052024-04-23Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.1750-2640http://hdl.handle.net/10400.18/10409Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65- to 79-year-olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.engCOVID-19SARS‐CoV‐2Cohort DesignElectronic Health RecordsVaccine EffectivenessHospitalisationMulticountry StudyVEBIS-Lot 4EuropeVacina COVID-19EfetividadeRegistos Eletrónicos em SaúdeCuidados de SaúdeInfecções Respiratóriasjournal article10.1111/irv.1329238654485